Drug Trial Radar · NCT04865939
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Nov 29, 2021
Primary completion
Nov 1, 2029
Study completion Nov 1, 2031
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical irrigation with sterile water has equivalent efficacy to intravesical chemotherapy in prevention of recurrent bladder cancer following transurethral resection of bladder tumors (TURBT). This study is intended to compare recurrence rates using intravesical gemcitabine (as a pseudo-standard of care) and continuous bladder irrigation with sterile water.
Conditions
- Urothelial Cancer of Renal Pelvis
- Urothelial Carcinoma Ureter
Interventions
sterile water irrigationProcedure
Continuous irrigation of bladder with sterile water during surgery (prior to entry into bladder).
GemcitabineDrug
Intravesical gemcitabine instilled into bladder during surgery (drained prior to entry into bladder).
Primary outcomes
What the sponsor says the trial is designed to measure.
- intravesical recurrenceTime frame: 1 year
- intravesical recurrenceTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Texas Southwestern Medical Center
Dallas, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.